Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials

Version 1 : Received: 17 October 2024 / Approved: 18 October 2024 / Online: 21 October 2024 (08:34:15 CEST)

How to cite: Mayasin, Y. P.; Osinnikova, M. N.; Kharisova, C. B.; Kitaeva, K. V.; Filin, I. Y.; Gorodilova, A. V.; Kutovoi, G. I.; Solovyeva, V. V.; Golubev, A. I.; Rizvanov, A. A. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints 2024, 2024101515. https://doi.org/10.20944/preprints202410.1515.v1 Mayasin, Y. P.; Osinnikova, M. N.; Kharisova, C. B.; Kitaeva, K. V.; Filin, I. Y.; Gorodilova, A. V.; Kutovoi, G. I.; Solovyeva, V. V.; Golubev, A. I.; Rizvanov, A. A. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints 2024, 2024101515. https://doi.org/10.20944/preprints202410.1515.v1

Abstract

Melanoma is a malignant, highly metastatic neoplasm showing increasing morbidity and mortality. Tumor invasion and angiogenesis are based on remodeling of the extracellular matrix (ECM). Selective inhibition of functional components of cell-ECM interaction, such as hyaluronic acid (HA), matrix metalloproteinases (MMPs), and integrins, may inhibit tumor progression and enhance the efficacy of combination treatment with checkpoint inhibitors (ICBs), chemotherapy, or immunotherapy. In this review, we have combined the results of different approaches targeting extracellular matrix elements in melanoma in preclinical and clinical studies. The identified limitations of many approaches, including side effects, low selectivity and toxicity, indicate the need for further studies to optimize therapy. Nevertheless, significant progress in expanding our understanding of tumor biology and the development of targeted therapies holds great promise for the early approaches developed several decades ago to inhibit metastasis through ECM targeting.

Keywords

melanoma; extracellular matrix; MMP; TIMP; integrins; CD44; hyaluronic acid; clinical trials

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.